Published in Breast Cancer Res on January 01, 2006
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst (2014) 3.43
Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat (2010) 2.49
A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst (2012) 2.34
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer (2011) 2.01
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev (2009) 1.73
RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest (2009) 1.71
Tracing the tumor lineage. Mol Oncol (2010) 1.56
Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Res (2008) 1.52
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer (2010) 1.46
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol (2013) 1.45
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. BMC Med Genomics (2008) 1.41
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer (2010) 1.29
Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res (2007) 1.29
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol (2010) 1.24
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biol (2010) 1.16
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res (2009) 1.12
Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev (2014) 1.11
The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers. Mol Cell Biol (2010) 1.10
Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer (2008) 1.09
Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. BMC Res Notes (2012) 1.08
A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas. Diagn Pathol (2012) 1.04
Can survival prediction be improved by merging gene expression data sets? PLoS One (2009) 1.04
Triple-negative breast cancers: an updated review on treatment options. Curr Oncol (2011) 1.03
The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology (2011) 1.02
Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer (2010) 1.02
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol (2011) 1.02
TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production. BMC Biol (2012) 1.01
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer (2011) 1.00
Triple-Negative Breast Cancer: Clinical and Histological Correlations. Breast Care (Basel) (2011) 1.00
Prevalence of molecular subtypes of invasive breast cancer: A retrospective study. Med J Armed Forces India (2015) 0.99
Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. Am J Pathol (2010) 0.99
Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol (2012) 0.98
Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. Mol Cancer Ther (2011) 0.96
Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care (Basel) (2011) 0.95
IRP2 regulates breast tumor growth. Cancer Res (2013) 0.94
Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J (2011) 0.94
Effects of age on the detection and management of breast cancer. Cancers (Basel) (2015) 0.94
New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol Histopathol (2010) 0.93
A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol (2013) 0.92
Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol (2013) 0.92
Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res (2013) 0.91
Management options in triple-negative breast cancer. Breast Cancer (Auckl) (2011) 0.90
Gene expression profiles and breast cancer metastasis: a genetic perspective. Clin Exp Metastasis (2009) 0.89
Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. Br J Cancer (2013) 0.88
Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol (2016) 0.86
Epidemiology of triple negative breast cancers. Breast Dis (2010) 0.86
Biomarker discovery for heterogeneous diseases. Cancer Epidemiol Biomarkers Prev (2013) 0.84
Stromal signature identifies basal breast cancers. Nat Med (2009) 0.84
Keeping an open mind: highlights and controversies of the breast cancer stem cell theory. Breast Cancer (Dove Med Press) (2012) 0.84
Mammographic density and molecular subtypes of breast cancer. Br J Cancer (2012) 0.83
Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. Br J Cancer (2013) 0.82
Genetic variants in one-carbon metabolism genes and breast cancer risk in European American and African American women. Int J Cancer (2015) 0.82
Clustering gene expression data with a penalized graph-based metric. BMC Bioinformatics (2011) 0.81
Gene expression profiles for predicting metastasis in breast cancer: a cross-study comparison of classification methods. ScientificWorldJournal (2012) 0.80
Prediction of breast cancer metastasis by gene expression profiles: a comparison of metagenes and single genes. Cancer Inform (2012) 0.80
Gene Expression Meta-Analysis Identifies Cytokine Pathways and 5q Aberrations Involved in Metastasis of ERBB2 Amplified and Basal Breast Cancer. Cancer Inform (2013) 0.80
Household income is associated with the p53 mutation frequency in human breast tumors. PLoS One (2013) 0.79
Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment. Oncotarget (2015) 0.79
Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. J Exp Clin Cancer Res (2010) 0.78
The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics (2013) 0.78
Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today (2015) 0.77
In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models. J Health Care Poor Underserved (2013) 0.77
Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clin Chem Lab Med (2011) 0.76
Comprehensive landscape of subtype-specific coding and non-coding RNA transcripts in breast cancer. Oncotarget (2016) 0.75
Relation between radiographic BI-RADS scores and triple negativity in patients with ductal carcinomas. Int J Clin Exp Med (2014) 0.75
Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. Oncol Lett (2016) 0.75
Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients. Oncotarget (2017) 0.75
Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle (2016) 0.75
p16 expression correlates with basal-like triple-negative breast carcinoma. Ecancermedicalscience (2013) 0.75
Mammary gland stem cells and their application in breast cancer. Oncotarget (2016) 0.75
Cancer progression modeling using static sample data. Genome Biol (2014) 0.75
Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer. Horm Cancer (2017) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med (1995) 5.85
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells (1998) 3.13
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer (2004) 2.29
Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res (2005) 2.26
Biologic and therapeutic role of HER2 in cancer. Oncogene (2003) 2.26
Correlation test to assess low-level processing of high-density oligonucleotide microarray data. BMC Bioinformatics (2005) 1.86
Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res (2004) 1.47
Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res (2004) 1.44
Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci (2004) 1.28
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer (2005) 1.18
Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. Clin Chem (2004) 1.13
Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int J Cancer (2005) 0.93
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 20.65
International network of cancer genome projects. Nature (2010) 20.35
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet (2006) 17.19
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med (2013) 13.92
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet (2009) 12.96
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods (2005) 7.87
Mapping human genetic diversity in Asia. Science (2009) 7.40
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Mobile phone use and the risk of acoustic neuroma. Epidemiology (2004) 6.04
Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet (2003) 5.99
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol (2006) 4.93
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res (2009) 4.47
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics (2005) 3.83
Origins and genetic legacy of Neolithic farmers and hunter-gatherers in Europe. Science (2012) 3.82
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Long-term mobile phone use and brain tumor risk. Am J Epidemiol (2005) 3.80
Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res (2008) 3.76
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 3.40
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells (2005) 3.16
Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst (2005) 3.02
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol (2004) 2.77
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet (2002) 2.72
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest (2004) 2.66
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A (2008) 2.64
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet (2010) 2.62
Revisiting Mendelian disorders through exome sequencing. Hum Genet (2011) 2.57
Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53
Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol (2005) 2.51
Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. Genome Res (2004) 2.47
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell (2008) 2.46
Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer (2006) 2.46
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Systematic review and meta-analysis of circulatory disease from exposure to low-level ionizing radiation and estimates of potential population mortality risks. Environ Health Perspect (2012) 2.42
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39